文献速递药物不良反应与药物警戒

羟氯喹治疗COVID-19与精神障碍:VigiBase药物警戒研究

Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
PubMed 文献 · Drug Saf · 2020-10-19

基于WHO VigiBase数据库,分析截至2020年6月16日COVID-19患者使用羟氯喹报告的精神障碍不良效应,并与其他抗COVID-19药物进行不比例性分析。在1754份羟氯喹报告中发现56例精神障碍不良效应,半数严重,包括4例自杀完成;与瑞德西韦、托珠单抗或洛匹那韦/利托那韦相比,羟氯喹报告精神障碍的风险升高(ROR 6.27,95%CI 2.74-14.35)。

要点

  • COVID-19患者使用羟氯喹报告56例精神障碍不良效应,半数严重。
  • 严重事件包括4例自杀完成、3例故意自伤和12例伴幻觉的精神病性障碍。
  • 与对照药物相比,羟氯喹报告精神障碍风险升高(ROR 6.27,95%CI 2.74-14.35)。

核心结论

  • 药物警戒分析提示COVID-19患者暴露于羟氯喹后出现严重精神障碍,部分患者自杀。
  • 需进一步真实世界研究量化COVID-19大流行期间羟氯喹相关精神风险。

研究设计与样本

  • 基于WHO VigiBase个体病例安全报告数据库的药物警戒研究。
  • 分析截至2020年6月16日COVID-19患者使用羟氯喹的所有精神障碍不良效应报告。
  • 采用不比例性分析,以瑞德西韦、托珠单抗或洛匹那韦/利托那韦为对照,计算报告比值比(ROR)及95%CI。
  • 同时回顾2020年前羟氯喹其他适应症的精神安全性特征。

主要发现

  • COVID-19患者羟氯喹报告共1754份,其中精神障碍不良效应56例。
  • 56例中半数严重,包括4例自杀完成、3例故意自伤和12例伴幻觉的精神病性障碍。
  • 与对照药物相比,羟氯喹报告精神障碍风险升高(ROR 6.27,95%CI 2.74-14.35)。
  • 2020年前,自杀是羟氯喹所有报告药物不良反应中的主要死亡原因,其后的心脏不良反应(心肌病)和呼吸衰竭。

临床怎么用

  • 临床使用羟氯喹治疗COVID-19时,应警惕精神障碍不良效应,包括自杀风险。
  • 对用药患者应监测精神症状变化,及时识别严重精神事件。

局限性

  • 研究基于自发报告数据库,可能存在报告偏倚和混杂因素。
  • 不比例性分析不能确定因果关系。
  • 需进一步真实世界研究量化精神风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the stressful context of the coronavirus disease 2019 (COVID-19) pandemic, some reports have raised concerns regarding psychiatric disorders with the use of hydroxychloroquine. In this study, we reviewed all psychiatric adverse effects with hydroxychloroquine in COVID-19 patients, as well as in other indications, reported in VigiBase, the World Health Organization's (WHO) global database of individual case safety reports. METHODS: First, we analyzed all psychiatric adverse effects, including suicide, of hydroxychloroquine in COVID-19 patients reported to 16 June 2020. We also performed disproportionality analysis to investigate the risk of reporting psychiatric disorders with hydroxychloroquine compared with remdesivir, tocilizumab, or lopinavir/ritonavir prescribed in COVID-19 patients. We used reporting odds ratios (RORs) and their 95% confidence intervals (CIs) to calculate disproportionality. Second, we sought to examine the psychiatric safety profile of hydroxychloroquine in other indications (before 2020). RESULTS: Among the 1754 reports with hydroxychloroquine in COVID-19 patients, we found 56 psychiatric adverse effects. Half of these adverse effects were serious, including four completed suicides, three cases of intentional self-injury, and 12 cases of psychotic disorders with hallucinations. Compared with remdesivir, tocilizumab, or lopinavir/ritonavir, the use of hydroxychloroquine was associated with an increased risk of reporting psychiatric disorders (ROR 6.27, 95% CI 2.74-14.35). Before 2020, suicide was the main cause of death among all adverse drug reactions reported with hydroxychloroquine, followed by cardiac adverse effects (cardiomyopathy) and respiratory failure. CONCLUSIONS: This pharmacovigilance analysis suggests that COVID-19 patients exposed to hydroxychloroquine experienced serious psychiatric disorders, and, among these patients, some committed suicide. Further real-world studies are needed to quantify the psychiatric risk associated with hydroxychloroquine during the COVID-19 pandemic.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Garcia P, Revet A, Yrondi A, et al. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study. Drug Saf. 2020. PMID: 33078372. doi:10.1007/s40264-020-01013-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。